Donanemab

Lormalzi Concentrate for Solution for Infusion 350mg/20mL

350mg/20mL infusion, solution concentrateSingaporeAuthorisedAuthorised 11 Mar 2025

In other countries

The same active substances on other registers, the same brand first.

KisunlaUnited States · 350MG/20ML · injectable · Eli Lilly CoSame strength and form
Kisunla 350 MG Concentrado Para Solucion Para PerfusionSpain · 350 mg · concentrado para solución para perfusión · Eli Lilly Nederland B.V.Same form
KisunlaItaly · Concentrato per soluzione per infusione · Eli Lilly Nederland B.V.Same form
Kisunla 350 mg concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Eli Lilly Nederland B.V.Same form
KisunlaBrazil · Eli Lilly do Brasil LtdaSame substance
KisunlaCanada · 17.5 MG / ML · Solution · Eli Lilly Canada INCSame substance
KisunlaEuropean Union · Eli Lilly Nederland B.V.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Donanemab

Lormalzi Concentrate for Solution for Infusion 350mg/20mL

350mg/20mL infusion, solution concentrateSingaporeAuthorisedAuthorised 11 Mar 2025

Ask Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

KisunlaCroatia

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Sciences Authority / data.gov.sg

Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence

Licence: Singapore Open Data Licence 1.0 · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Donanemab
Strength: 350mg/20mL
Dosage form: infusion, solution concentrate
Route: intravenous
Register: Singapore (HSA)
Status: Authorised
Status in the register: Registered
Authorised: 11 Mar 2025
Registration: SIN17201P
Marketing authorisation holder: DKSH Singapore Pte. LTD.
Manufacturer: Lilly France, FRANCE
ATC code: N06DX05
Group: Nervous system
Supply: Prescription Only